Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Alzheimers Dement. 2018 Oct 12;15(1):55–64. doi: 10.1016/j.jalz.2018.08.006

Table 2.

Spearman’s correlation analysis of GAP-43 concentration with CSF biomarkers of Alzheimer’s disease pathology

IB AlzBio3 T-tau (pg/mL)
 IB AlzBio3 Aβ42 (pg/mL)
 IB AlzBio3 PTau (pg/mL)
Diagnostic group rs P n rs P n rs P n
Control 0.841 <.0001  42 −0.083  .595  43  0.356  .019  43
All MCI 0.908 <.0001  83 −0.066  .551  83  0.649 <.0001  83
AD 0.818 <.0001 261 −0.131  .034 262  0.516 <.0001 262
ALS 0.806 <.0001  52  0.531 <.0001  53  0.456  .001  52
FTD 0.752 <.0001  32  0.149  .408  33  0.384  .03  32
PD not demented 0.639 <.0001  26  0.346  .083  26  0.055  .791  26
PD-MCI 0.7  .005  14 −0.407  .149  14  0.569  .034  14
PD with dementia 0.688  .007  14  0.368  .177  15  0.45  .092  15
DLB 0.892 <.0001  18 −0.077  .753  19  0.522  .022  19
PPA 0.782 <.0001  31  0.092  .621  31  0.207  .265  31
PSP 0.829 <.0001  17  0.437  .08  17  0.692  .002  17
Corticobasal syndrome 0.676  .011  13  0.407  .168  13 −0.58  .851  13

Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; PD, Parkinson’s disease; DLB, dementia with Lewy bodies; PPA, primary progressive aphasia; PSP, progressive supranuclear palsy.